Mecligold Tablet SR is a sustained-release formulation combining Meclizine 50mg and Folic Acid 5mg, designed to provide effective relief from vertigo, motion sickness, and nausea while supporting hematological health. Meclizine, an antihistamine with anticholinergic properties, acts by inhibiting vestibular stimulation in the inner ear, thereby reducing symptoms associated with motion sickness and vertigo such as dizziness, nausea, and vomiting. The sustained-release mechanism ensures prolonged therapeutic action, enhancing patient compliance by reducing dosing frequency. Folic Acid, a vital B-vitamin, is included to support red blood cell formation and prevent folate deficiency, which is particularly beneficial in populations at risk of anemia or during pregnancy. The combination is indicated for patients requiring symptomatic management of vestibular disorders alongside folate supplementation. Mecligold Tablet SR should be administered under medical supervision, with dosage adjusted according to clinical response. Caution is advised in patients with hypersensitivity to antihistamines, glaucoma, or prostatic hypertrophy. Common adverse effects may include drowsiness, dry mouth, and gastrointestinal disturbances. This formulation offers a dual therapeutic approach, addressing both vestibular symptoms and nutritional needs, thereby enhancing overall patient outcomes.